<DOC>
	<DOCNO>NCT01420549</DOCNO>
	<brief_summary>The purpose study determine non-inferiority two different FDC , measure LDL-Cholesterol level , high risk patient NCEP-ATP III , primary hypercholesterolemia mixed dyslipidemia .</brief_summary>
	<brief_title>Efficacy Safety FDC High Risk Patients With Primary Hypercholesterolemia Mixed Dyslipidemia</brief_title>
	<detailed_description>The propose study evaluate efficacy combination Rosuvastatin + Ezetimibe noninferiority compare simvastatin + ezetimibe combination - Vytorin ® - control LDL cholesterol compare baseline stipulate high-risk patient NCEP-ATP III , patient primary hypercholesterolemia mixed dyslipidemia .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients sex , age 18 70 year , remain feasibility legal guardian accordance need , able understand provide write informed consent able allow compliance treatment requirement protocol ; Confirmed diagnosis primary hypercholesterolemia ; Confirmed diagnosis mixed dyslipidemia ; Liver transaminases ≤ 2 x upper limit normal active liver disease ; Creatinine kinase ( CK ) less equal upper limit normality ; Patients clinically significant comorbidities , may interfere evaluation study ; Patients willing maintain cholesterollowering diet throughout study ; Patients need agree discontinue previous medication hypercholesterolemia treatment switch study medication . Patients primary hypercholesterolemia LDLC &gt; 160 mg/dl &lt; 220 mg/dl ; triglyceride ( TG ) concentration &lt; 350 mg/dl Heart failure class III IV ( NYHA ) ; Blood dyscrasia ; Unstable angina pectoris ; Myocardial infarction last 3 month ; Planning CABG , peripheral carotid percutaneous intervention next 90 day ; Renal insufficiency ( estimate GFR &lt; 30 ml/min/m2 ) ; Liver transaminases &gt; 2 x upper limit normal ; Asian patient kinship asian ; History alcoholism drug abuse ; Patients comorbidities hinder interpretation result contraindicate lipidlowering therapy [ uncompensated hypothyroidism ( TSH &gt; 8 mUI/mL ) ; uncompensated diabetes ( HbA1c &gt; 8 % ) ; active hepatic disease ; antiretroviral therapy , neoplasm ( except adequately treat squamous cell skin cancer within past 5 year ) , concomitant immunosuppressive therapy ( transplant rheumatic disease ) . Noncompensated hypertension ( BP ≥ 160/100 mm Hg ) ; Women childbearing age test positive pregnancy , use acceptable contraceptive method , agree practice reliable contraception study ; Woman pregnancy lactation period ; Hypersensibility ezetimibe rosuvastatin , component medication ; Participation last one year clinical protocol , unless direct benefit patient ; Any find clinical observation ( anamnesis physical exam ) laboratory abnormality ( eg , blood glucose , blood count ) , disease ( example , liver , cardiovascular system , lung ) therapy , opinion investigator , may endanger subject interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>